Development of enzyme-linked immunosorbent assays for the detection of myositis-specific autoantibodies against signal recognition particle, nuclear matrix protein 2, and small ubiquitin-like modifier activating enzyme
Modern Rheumatology · 2026
DOI: 10.1093/mr/roag003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2026. Verfasst von Akihiro Murakami und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical & Biological Laboratories Co., Ltd, Tokyo, Japan. Hauptthemen laut MEDLINE: Autoantibodies, Signal Recognition Particle, Myositis, RNA-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To develop and validate enzyme-linked immunosorbent assay (ELISA) systems for the detection of autoantibodies against the signal recognition particle (SRP), nuclear matrix protein 2 (NXP2), and small ubiquitin-like modifier activating enzyme (SAE).
Methods
Serum samples from 288 individuals were analysed, including 183 patients with idiopathic inflammatory myopathies, 20 with other neuromuscular diseases, 35 with non-idiopathic inflammatory myopathies and other systemic autoimmune rheumatic diseases, and 50 healthy controls. ELISA systems were established using recombinant SRP, NXP2, and SAE proteins expressed in insect cells or Escherichia coli. The diagnostic performance of the ELISAs was assessed in comparison with the ‘gold-standard’ immunoprecipitation assays.
Results
The ELISAs demonstrated high concordance with immunoprecipitation assays, with positive and negative percent agreements of 97.4% and 100% for anti-SRP, 100% and 99.6% for anti-NXP2, and 100% and 99.6% for anti-SAE antibodies, respectively.
Conclusions
The newly developed ELISA systems showed excellent agreement with immunoprecipitation assays, supporting their applicability for routine clinical use in detecting anti-SRP, anti-NXP2, and anti-SAE autoantibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical & Biological Laboratories Co., Ltd, Tokyo, Japan.
- Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
- Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- Department of Dermatology, Graduate School of Medicine, Osaka University, Osaka, Japan.
- Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
ORCID-Profile: Masataka Kuwana
Zitieren
APA
Murakami, A., Abe, H., Kikuchi, T., Kidani, S., Nishikawa, Y., Isayama, T., Matsuzawa, S., Sato, S., Nakashima, R., Okiyama, N., Fujimoto, M., Nishino, I., & Kuwana, M. (2026). Development of enzyme-linked immunosorbent assays for the detection of myositis-specific autoantibodies against signal recognition particle, nuclear matrix protein 2, and small ubiquitin-like modifier activating enzyme. Modern Rheumatology. https://doi.org/10.1093/mr/roag003
Vancouver
Murakami A, Abe H, Kikuchi T, Kidani S, Nishikawa Y, Isayama T, et al. Development of enzyme-linked immunosorbent assays for the detection of myositis-specific autoantibodies against signal recognition particle, nuclear matrix protein 2, and small ubiquitin-like modifier activating enzyme. Modern Rheumatology. 2026. doi:10.1093/mr/roag003
BibTeX
@article{Murakami2026,
author = {Murakami, Akihiro and Abe, Hiroki and Kikuchi, Tetsuya and Kidani, Shunsuke and Nishikawa, Yukihiro and Isayama, Takuya and Matsuzawa, Shun and Sato, Shinji and Nakashima, Ran and Okiyama, Naoko and Fujimoto, Manabu and Nishino, Ichizo and Kuwana, Masataka},
title = {Development of enzyme-linked immunosorbent assays for the detection of myositis-specific autoantibodies against signal recognition particle, nuclear matrix protein 2, and small ubiquitin-like modifier activating enzyme},
journal = {Modern Rheumatology},
year = {2026},
doi = {10.1093/mr/roag003}
}
EUVIMED